Advertisement

 

 

The challenges of pharmacokinetic variability of first-line anti-TB drugs.

The challenges of pharmacokinetic variability of first-line anti-TB drugs.
Author Information (click to view)

Devaleenal D B, Ramachandran G, Swaminathan S,


Devaleenal D B, Ramachandran G, Swaminathan S, (click to view)

Devaleenal D B, Ramachandran G, Swaminathan S,

Advertisement
Share on FacebookTweet about this on TwitterShare on LinkedIn

Expert review of clinical pharmacology 2016 Oct 11()

Abstract
INTRODUCTION
Inter-individual variations in the pharmacokinetics (PK) of anti-TB drugs are known to occur, which could have important therapeutic implications in patient management. Areas covered: We compiled factors responsible for PK variability of anti-TB drugs reported from different settings that would give a better understanding about the challenges of PK variability of anti-TB medications. We searched PubMed data base and Google scholar from 1976 to the present using the key words "Pharmacokinetics", "pharmacokinetic variability", "first-line anti-TB therapy", "Rifampicin", "Isoniazid", "Ethambutol", "Pyrazinamide", "food", "nutritional status", "HIV", "diabetes", "genetic polymorphisms" and "pharmacokinetic interactions". We also included abstracts from scientific meetings and review articles. Expert commentary: A variety of host and genetic factors can cause inter-individual variations in the PK of anti-TB drugs. PK studies conducted in various settings have adopted different designs, PK sampling time points, drug estimation methodologies. Hence comparison and interpretation of these results should be done with caution More phamacogenomic studies in different patient populations are needed for further understanding.

Submit a Comment

Your email address will not be published. Required fields are marked *

six + 12 =

[ HIDE/SHOW ]